Neuroprotection
What Is Semax?
A research-first explanation of Semax, its ACTH-fragment origin, verified study coverage, and where the evidence remains bounded.
Definition and catalog identity
Semax is represented in the Atlas catalog as an ACTH-fragment-derived heptapeptide. Its profile is anchored to verified PubMed records and internal comparison pages rather than consumer claims.
The core editorial question is not whether Semax has publications. It does. The question is which parts of the literature are human, animal, cellular, or review-level evidence.
Research themes
The verified Semax set spans ischemia, transcriptomic signaling, neurotrophin-related models, connectomic work, and newer injury-model publications.
Atlas treats neurotrophic and recovery language as hypothesis context unless a specific study design supports a narrower statement.
Evidence boundary
Phase 3 expands Semax coverage with PubMed-verified citation records while preserving the extraction distinction between full abstract review and metadata verification.
Human-facing interpretation should prioritize the extracted human rehabilitation records and keep animal or molecular studies in their own evidence lane.
Sources and further reading
- 01Open source
Semax literature index
PubMed, U.S. National Library of Medicine · Database